	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	GRP	study	notes	organ	type.endpt	endpoint	species	strain	sex	route	exp.regime	hrs.day	days.wk	expos. wk
2	2	Fukuda83	0 ppm dose group (medium default BW)	Lung	cancer	ad+car	mouse	Crj:CD-1 (ICR)	F	inhal	7h/d, 5d/w, 104 wk sac	7	5	104
3	2	Fukuda83	50 ppm dose group (medium default BW)	Lung	cancer	ad+car	mouse	Crj:CD-1 (ICR)	F	inhal	7h/d, 5d/w, 104 wk sac	7	5	104
4	2	Fukuda83	150 ppm dose group (medium default BW)	Lung	cancer	ad+car	mouse	Crj:CD-1 (ICR)	F	inhal	7h/d, 5d/w, 104 wk sac	7	5	104
5	2	Fukuda83	450 ppm dose group (medium default BW)	Lung	cancer	ad+car	mouse	Crj:CD-1 (ICR)	F	inhal	7h/d, 5d/w, 104 wk sac	7	5	104
6	3	Henschler80	0 ppm dose group (medium default BW)	Hematopoietic	cancer	lymphomas	mouse	Han:NMRI	F	inhal	6h/d, 5d/w, 18 mo exp, 30 mo sac	6	5	78
7	3	Henschler80	100 ppm dose group (medium default BW)	Hematopoietic	cancer	lymphomas	mouse	Han:NMRI	F	inhal	6h/d, 5d/w, 18 mo exp, 30 mo sac	6	5	78
8	3	Henschler80	500 ppm dose group (medium default BW)	Hematopoietic	cancer	lymphomas	mouse	Han:NMRI	F	inhal	6h/d, 5d/w, 18 mo exp, 30 mo sac	6	5	78
9	4	Maltoni86	0 ppm dose group (BT306)	Lung	cancer	ad+car	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
10	4	Maltoni86	100 ppm dose group (BT306)	Lung	cancer	ad+car	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
11	4	Maltoni86	300 ppm dose group (BT306)	Lung	cancer	ad+car	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
12	4	Maltoni86	600 ppm dose group (BT306)	Lung	cancer	ad+car	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
13	5.1	Maltoni86	0 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
14	5.1	Maltoni86	100 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
15	5.1	Maltoni86	300 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
16	5.1	Maltoni86	600 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
17	5.05	Maltoni86	0 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
18	5.05	Maltoni86	100 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
19	5.05	Maltoni86	300 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
20	5.05	Maltoni86	600 ppm dose group (BT306)	Liver	cancer	hepatoma	mouse	B6C3F1	F	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
1	sac.wk	adjust	adj.hd	adj.exp	adj.sac	BW.kg	resp.type	dose.units	appl.dose	N	Y	N.m.Y	BMR.type	BMR	ABioactDCVCBW34.median	AMetGSHBW34.median	AMetLiv1BW34.median	AMetLngBW34.median	AUCCBld.median	TotMetabBW34.median	TotOxMetabBW34.median
2	104	0.208333	0.20833	1	1	0.028	dichot	ppm	0	49	6	43	extra	0.1	0	0	0	0	0	0	0
3	104	0.208333	0.20833	1	1	0.028	dichot	ppm	50	50	5	45	extra	0.1	0.1434795	0.326556	81.03205	128.476	44.79885	214.7985	212.2895
4	104	0.208333	0.20833	1	1	0.028	dichot	ppm	150	50	13	37	extra	0.1	0.465201	1.02615	257.524	210.01	154.905	510.52	507.6005
5	104	0.208333	0.20833	1	1	0.028	dichot	ppm	450	46	11	35	extra	0.1	1.6246	3.647095	709.055	247.5865	570.4765	1055.895	1050.68
6	130	0.133929	0.17857	0.75	1	0.028	dichot	ppm	0	29	6	23	extra	0.1	0	0	0	0	0	0	0
7	130	0.133929	0.17857	0.75	1	0.028	dichot	ppm	100	30	11	19	extra	0.1	0.2578235	0.582824	145.254	159.3065	83.3496	321.4795	320.0005
8	130	0.133929	0.17857	0.75	1	0.028	dichot	ppm	500	29	12	17	extra	0.1	1.58599	3.53273	658.8795	219.6815	558.273	973.6125	968.145
9	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	0	90	2	88	extra	0.1	0	0	0	0	0	0	0
10	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	100	90	6	84	extra	0.1	0.3040715	0.6840495	169.702	187.2525	96.94025	376.6295	374.5945
11	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	300	89	7	82	extra	0.1	1.00948	2.240755	508.444	237.395	345.5335	835.627	830.0405
12	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	600	87	14	73	extra	0.1	2.350125	5.152295	877.545	263.377	821.938	1261.625	1252.14
13	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	0	88	3	85	extra	0.1	0	0	0	0	0	0	0
14	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	100	89	4	85	extra	0.1	0.3040715	0.6840495	169.702	187.2525	96.94025	376.6295	374.5945
15	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	300	88	4	84	extra	0.1	1.00948	2.240755	508.444	237.395	345.5335	835.627	830.0405
16	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	600	85	9	76	extra	0.1	2.350125	5.152295	877.545	263.377	821.938	1261.625	1252.14
17	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	0	88	3	85	extra	0.05	0	0	0	0	0	0	0
18	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	100	89	4	85	extra	0.05	0.3040715	0.6840495	169.702	187.2525	96.94025	376.6295	374.5945
19	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	300	88	4	84	extra	0.05	1.00948	2.240755	508.444	237.395	345.5335	835.627	830.0405
20	life	0.15625	0.20833	0.75	1	0.03	dichot	ppm	600	85	9	76	extra	0.05	2.350125	5.152295	877.545	263.377	821.938	1261.625	1252.14

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	GRP	study	notes	organ	type.endpt	endpoint	species	strain	sex	route	exp.regime	hrs.day	days.wk	expos. wk
21	9	Maltoni86	0 ppm dose group (BT305)	Liver	cancer	hepatoma	mouse	Swiss	M	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
22	9	Maltoni86	100 ppm dose group (BT305)	Liver	cancer	hepatoma	mouse	Swiss	M	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
23	9	Maltoni86	300 ppm dose group (BT305)	Liver	cancer	hepatoma	mouse	Swiss	M	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
24	9	Maltoni86	600 ppm dose group (BT305)	Liver	cancer	hepatoma	mouse	Swiss	M	inhal	7h/d, 5d/w, 78wk exp, nat.life	7	5	78
25	10	NCI76	0 mg/kg-d avg.over.78 wk Low-Dose Group	Liver	cancer	hepatocellular carcinoma	mouse	B6C3F1	M	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
26	10	NCI76	1169 mg/kg-d avg.over.78 wk Low-Dose Group	Liver	cancer	hepatocellular carcinoma	mouse	B6C3F1	M	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
27	10	NCI76	2339 mg/kg-d avg.over.78 wk High-Dose Group	Liver	cancer	hepatocellular carcinoma	mouse	B6C3F1	M	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
28	11	NCI76	0 mg/kg-d avg.over.78 wk Low-Dose Group	Liver	cancer	hepatocellular carcinoma	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
29	11	NCI76	869 mg/kg-d avg.over.78 wk Low-Dose Group	Liver	cancer	hepatocellular carcinoma	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
30	11	NCI76	1739 mg/kg-d avg.over.78 wk High-Dose Group	Liver	cancer	hepatocellular carcinoma	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
31	12	NCI76	0 mg/kg-d avg.over.78 wk Low-Dose Group	Lung	cancer	ad+car	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
32	12	NCI76	869 mg/kg-d avg.over.78 wk Low-Dose Group	Lung	cancer	ad+car	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
33	12	NCI76	1739 mg/kg-d avg.over.78 wk High-Dose Group	Lung	cancer	ad+car	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
34	13	NCI76	0 mg/kg-d avg.over.78 wk Low-Dose Group	multiple	cancer	sarcomas+lymphomas	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
35	13	NCI76	869 mg/kg-d avg.over.78 wk Low-Dose Group	multiple	cancer	sarcomas+lymphomas	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
36	13	NCI76	1739 mg/kg-d avg.over.78 wk High-Dose Group	multiple	cancer	sarcomas+lymphomas	mouse	B6C3F1	F	oral	5d/w, exp.78wk, sac 91 wk	24	5	78
37	18.1	Maltoni86	0 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
38	18.1	Maltoni86	100 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
39	18.1	Maltoni86	300 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
1	sac.wk	adjust	adj.hd	adj.exp	adj.sac	BW.kg	resp.type	dose.units	appl.dose	N	Y	N.m.Y	BMR.type	BMR	ABioactDCVCBW34.median	AMetGSHBW34.median	AMetLiv1BW34.median	AMetLngBW34.median	AUCCBld.median	TotMetabBW34.median	TotOxMetabBW34.median
21	life	0.15625	0.20833	0.75	1	0.04493	dichot	ppm	0	66	4	62	extra	0.1	0	0	0	0	0	0	0
22	life	0.15625	0.20833	0.75	1	0.04493	dichot	ppm	100	53	2	51	extra	0.1	0.315282	0.7104155	170.351	199.543	94.5921	387.9585	385.667
23	life	0.15625	0.20833	0.75	1	0.04493	dichot	ppm	300	59	8	51	extra	0.1	1.04244	2.329795	517.2845	261.369	334.894	873.718	868.724
24	life	0.15625	0.20833	0.75	1	0.04493	dichot	ppm	600	61	13	48	extra	0.1	2.40418	5.328415	918.3415	289.6715	787.743	1336.555	1330.345
25	91	0.410156	0.71429	0.857143	0.6699	0.0315	dichot	mg.kgd	0	20	1	19	extra	0.1	0	0	0	0	0	0	0
26	91	0.410156	0.71429	0.857143	0.6699	0.0315	dichot	mg.kgd	1169	48	26	22	extra	0.1	3.4165111	7.72715483	970.425363	144.36119	738.089243	1233.59855	1217.58978
27	91	0.410156	0.71429	0.857143	0.6699	0.0315	dichot	mg.kgd	2339	41	31	10	extra	0.1	7.39457826	15.1853055	1378.80211	235.937543	1819.95079	1788.23344	1755.55644
28	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	0	18	0	18	extra	0.1	0	0	0	0	0	0	0
29	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	869	45	4	41	extra	0.1	2.23430625	5.14186248	768.690775	106.968646	474.33621	969.23653	957.307385
30	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	1739	41	11	30	extra	0.1	4.88290194	10.6197888	1124.71594	184.899246	1191.22167	1436.26703	1416.77894
31	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	0	18	1	17	extra	0.1	0	0	0	0	0	0	0
32	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	869	45	4	41	extra	0.1	2.23430625	5.14186248	768.690775	106.968646	474.33621	969.23653	957.307385
33	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	1739	41	7	34	extra	0.1	4.88290194	10.6197888	1124.71594	184.899246	1191.22167	1436.26703	1416.77894
34	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	0	18	1	17	extra	0.1	0	0	0	0	0	0	0
35	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	869	45	5	40	extra	0.1	2.23430625	5.14186248	768.690775	106.968646	474.33621	969.23653	957.307385
36	91	0.410156	0.71429	0.857143	0.6699	0.0258	dichot	mg.kgd	1739	41	6	35	extra	0.1	4.88290194	10.6197888	1124.71594	184.899246	1191.22167	1436.26703	1416.77894
37	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	134	9	125	extra	0.1	0	0	0	0	0	0	0
38	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	130	13	117	extra	0.1	0.383894	0.3770245	179.207	17.5567	82.19865	214.654	214.196
39	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	130	14	116	extra	0.1	0.934892	0.91368	457.814	22.95885	337.0005	507.0845	505.5335

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	GRP	study	notes	organ	type.endpt	endpoint	species	strain	sex	route	exp.regime	hrs.day	days.wk	expos. wk
40	18.1	Maltoni86	600 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
41	18.05	Maltoni86	0 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
42	18.05	Maltoni86	100 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
43	18.05	Maltoni86	300 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
44	18.05	Maltoni86	600 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
45	18.11	Maltoni86	0 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
46	18.11	Maltoni86	100 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
47	18.11	Maltoni86	300 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
48	18.051	Maltoni86	0 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
49	18.051	Maltoni86	100 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
50	18.051	Maltoni86	300 ppm dose group (combine 304+304bis)	hematopoietic	cancer	leukemia	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
51	19.1	Maltoni86	0 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
52	19.1	Maltoni86	100 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
53	19.1	Maltoni86	300 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
54	19.1	Maltoni86	600 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
55	19.01	Maltoni86	0 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
56	19.01	Maltoni86	100 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
57	19.01	Maltoni86	300 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
58	19.01	Maltoni86	600 ppm dose group (combine 304+304bis)	Kidney	cancer	car+ad	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
1	sac.wk	adjust	adj.hd	adj.exp	adj.sac	BW.kg	resp.type	dose.units	appl.dose	N	Y	N.m.Y	BMR.type	BMR	ABioactDCVCBW34.median	AMetGSHBW34.median	AMetLiv1BW34.median	AMetLngBW34.median	AUCCBld.median	TotMetabBW34.median	TotOxMetabBW34.median
40	life	0.208333	0.20833	1	1	0.565	dichot	ppm	600	129	15	114	extra	0.1	2.27703	2.31345	704.283	28.92445	1032.09	764.479	760.705
41	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	134	9	125	extra	0.05	0	0	0	0	0	0	0
42	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	130	13	117	extra	0.05	0.383894	0.3770245	179.207	17.5567	82.19865	214.654	214.196
43	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	130	14	116	extra	0.05	0.934892	0.91368	457.814	22.95885	337.0005	507.0845	505.5335
44	life	0.208333	0.20833	1	1	0.565	dichot	ppm	600	129	15	114	extra	0.05	2.27703	2.31345	704.283	28.92445	1032.09	764.479	760.705
45	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	134	9	125	extra	0.1							
46	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	130	13	117	extra	0.1							
47	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	130	14	116	extra	0.1							
48	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	134	9	125	extra	0.05							
49	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	130	13	117	extra	0.05							
50	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	130	14	116	extra	0.05							
51	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	121	0	121	extra	0.1	0	0	0	0	0	0	0
52	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	118	1	117	extra	0.1	0.383894	0.3770245	179.207	17.5567	82.19865	214.654	214.196
53	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	116	0	116	extra	0.1	0.934892	0.91368	457.814	22.95885	337.0005	507.0845	505.5335
54	life	0.208333	0.20833	1	1	0.565	dichot	ppm	600	123	5	118	extra	0.1	2.27703	2.31345	704.283	28.92445	1032.09	764.479	760.705
55	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	121	0	121	extra	0.01	0	0	0	0	0	0	0
56	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	118	1	117	extra	0.01	0.383894	0.3770245	179.207	17.5567	82.19865	214.654	214.196
57	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	116	0	116	extra	0.01	0.934892	0.91368	457.814	22.95885	337.0005	507.0845	505.5335
58	life	0.208333	0.20833	1	1	0.565	dichot	ppm	600	123	5	118	extra	0.01	2.27703	2.31345	704.283	28.92445	1032.09	764.479	760.705

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	GRP	study	notes	organ	type.endpt	endpoint	species	strain	sex	route	exp.regime	hrs.day	days.wk	expos. wk
59	20	Maltoni86	0 ppm dose group (combine 304+304bis)	Testis	cancer	Leydig cell tumor	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
60	20	Maltoni86	100 ppm dose group (combine 304+304bis)	Testis	cancer	Leydig cell tumor	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
61	20	Maltoni86	300 ppm dose group (combine 304+304bis)	Testis	cancer	Leydig cell tumor	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
62	20	Maltoni86	600 ppm dose group (combine 304+304bis)	Testis	cancer	Leydig cell tumor	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
63	20.1	Maltoni86	0 ppm dose group (combine 304+304bis)	Testis	cancer	Leydig cell tumor	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
64	20.1	Maltoni86	100 ppm dose group (combine 304+304bis)	Testis	cancer	Leydig cell tumor	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
65	20.1	Maltoni86	300 ppm dose group (combine 304+304bis)	Testis	cancer	Leydig cell tumor	rat	Sprague-Dawley	M	inhal	7h/d, 5d/w, 104 w exp, nat.life	7	5	104
66	22	NTP90	0 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
67	22	NTP90	500 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
68	22	NTP90	1000 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
69	22.21	NTP90.p3	0 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
70	22.21	NTP90.p3	500 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
71	22.21	NTP90.p3	1000 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
72	22.05	NTP90	0 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
73	22.05	NTP90	500 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
74	22.05	NTP90	1000 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
75	22.205	NTP90.p3	0 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
76	22.205	NTP90.p3	500 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103
77	22.205	NTP90.p3	1000 mg/kg-d dose group	Kidney	cancer	car+ad	rat	F344/N	M	oral	5d/w, 103 wk dosed, 106 wk cntrl	24	5	103

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
1	sac.wk	adjust	adj.hd	adj.exp	adj.sac	BW.kg	resp.type	dose.units	appl.dose	N	Y	N.m.Y	BMR.type	BMR	ABioactDCVCBW34.median	AMetGSHBW34.median	AMetLiv1BW34.median	AMetLngBW34.median	AUCCBld.median	TotMetabBW34.median	TotOxMetabBW34.median
59	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	121	6	115	extra	0.1	0	0	0	0	0	0	0
60	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	116	16	100	extra	0.1	0.383894	0.3770245	179.207	17.5567	82.19865	214.654	214.196
61	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	116	30	86	extra	0.1	0.934892	0.91368	457.814	22.95885	337.0005	507.0845	505.5335
62	life	0.208333	0.20833	1	1	0.565	dichot	ppm	600	122	31	91	extra	0.1	2.27703	2.31345	704.283	28.92445	1032.09	764.479	760.705
63	life	0.208333	0.20833	1	1	0.565	dichot	ppm	0	121	6	115	extra	0.1							
64	life	0.208333	0.20833	1	1	0.565	dichot	ppm	100	116	16	100	extra	0.1							
65	life	0.208333	0.20833	1	1	0.565	dichot	ppm	300	116	30	86	extra	0.1							
66	103	0.714286	0.71429	1	1	0.384	dichot	mg.kgd	0	47	0	47	extra	0.1	0	0	0	0	0	0	0
67	103	0.714286	0.71429	1	1	0.357	dichot	mg.kgd	500	46	2	44	extra	0.1	4.18241	4.162075	753.637	23.0966	1396.715	802.2065	793.0615
68	103	0.714286	0.71429	1	1	0.34	dichot	mg.kgd	1000	34	3	31	extra	0.1	9.40237	9.34745	990.3775	33.6115	3440.69	1075.235	1054.515
69	103	0.714286	0.71429	1	1	0.384	dichot	mg.kgd	0	42	0	47	extra	0.1	0	0	0	0	0	0	0
70	103	0.714286	0.71429	1	1	0.357	dichot	mg.kgd	500	36	2	44	extra	0.1	4.18241	4.162075	753.637	23.0966	1396.715	802.2065	793.0615
71	103	0.714286	0.71429	1	1	0.34	dichot	mg.kgd	1000	26	3	31	extra	0.1	9.40237	9.34745	990.3775	33.6115	3440.69	1075.235	1054.515
72	103	0.714286	0.71429	1	1	0.384	dichot	mg.kgd	0	47	0	47	extra	0.05	0	0	0	0	0	0	0
73	103	0.714286	0.71429	1	1	0.357	dichot	mg.kgd	500	46	2	44	extra	0.05	4.18241	4.162075	753.637	23.0966	1396.715	802.2065	793.0615
74	103	0.714286	0.71429	1	1	0.34	dichot	mg.kgd	1000	34	3	31	extra	0.05	9.40237	9.34745	990.3775	33.6115	3440.69	1075.235	1054.515
75	103	0.714286	0.71429	1	1	0.384	dichot	mg.kgd	0	42	0	47	extra	0.05	0	0	0	0	0	0	0
76	103	0.714286	0.71429	1	1	0.357	dichot	mg.kgd	500	36	2	44	extra	0.05	4.18241	4.162075	753.637	23.0966	1396.715	802.2065	793.0615
77	103	0.714286	0.71429	1	1	0.34	dichot	mg.kgd	1000	26	3	31	extra	0.05	9.40237	9.34745	990.3775	33.6115	3440.69	1075.235	1054.515

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	GRP	study	notes	organ	type.endpt	endpoint	species	strain	sex	route	exp.regime	hrs.day	days.wk	expos. wk
78	23.1	NTP88	0 mg/kg-d dose group	hematopoietic	cancer	leukemia	rat	August	F	oral	5d/w, 104 w	24	5	103
79	23.1	NTP88	500 mg/kg-d dose group	hematopoietic	cancer	leukemia	rat	August	F	oral	5d/w, 104 w	24	5	103
80	23.1	NTP88	1000 mg/kg-d dose group	hematopoietic	cancer	leukemia	rat	August	F	oral	5d/w, 104 w	24	5	103
81	23.05	NTP88	0 mg/kg-d dose group	hematopoietic	cancer	leukemia	rat	August	F	oral	5d/w, 104 w	24	5	103
82	23.05	NTP88	500 mg/kg-d dose group	hematopoietic	cancer	leukemia	rat	August	F	oral	5d/w, 104 w	24	5	103
83	23.05	NTP88	1000 mg/kg-d dose group	hematopoietic	cancer	leukemia	rat	August	F	oral	5d/w, 104 w	24	5	103
84	24.1	NTP88	0 mg/kg-d dose group	Other	cancer	subcut tissue sarcoma	rat	August	M	oral	5d/w, 104 w	24	5	103
85	24.1	NTP88	500 mg/kg-d dose group	Other	cancer	subcut tissue sarcoma	rat	August	M	oral	5d/w, 104 w	24	5	103
86	24.1	NTP88	1000 mg/kg-d dose group	Other	cancer	subcut tissue sarcoma	rat	August	M	oral	5d/w, 104 w	24	5	103
87	24.05	NTP88	0 mg/kg-d dose group	Other	cancer	subcut tissue sarcoma	rat	August	M	oral	5d/w, 104 w	24	5	103
88	24.05	NTP88	500 mg/kg-d dose group	Other	cancer	subcut tissue sarcoma	rat	August	M	oral	5d/w, 104 w	24	5	103
89	24.05	NTP88	1000 mg/kg-d dose group	Other	cancer	subcut tissue sarcoma	rat	August	M	oral	5d/w, 104 w	24	5	103
90	25	NTP88	0 mg/kg-d dose group	Testis	cancer	Interstitial Cell Tumor	rat	Marshall	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
91	25	NTP88	500 mg/kg-d dose group	Testis	cancer	Interstitial Cell Tumor	rat	Marshall	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
92	25	NTP88	1000 mg/kg-d dose group	Testis	cancer	Interstitial Cell Tumor	rat	Marshall	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
93	25.2	NTP88.p3	0 mg/kg-d dose group	Testis	cancer	Interstitial Cell Tumor	rat	Marshall	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
94	25.2	NTP88.p3	500 mg/kg-d dose group	Testis	cancer	Interstitial Cell Tumor	rat	Marshall	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
95	25.2	NTP88.p3	1000 mg/kg-d dose group	Testis	cancer	Interstitial Cell Tumor	rat	Marshall	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
96	28	NTP88	0 mg/kg-d dose group	Kidney	cancer	car+ad	rat	Osborne-Mendel	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
97	28	NTP88	500 mg/kg-d dose group	Kidney	cancer	car+ad	rat	Osborne-Mendel	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
98	28	NTP88	1000 mg/kg-d dose group	Kidney	cancer	car+ad	rat	Osborne-Mendel	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
99	28.2	NTP88.p3	0 mg/kg-d dose group	Kidney	cancer	car+ad	rat	Osborne-Mendel	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
1	sac.wk	adjust	adj.hd	adj.exp	adj.sac	BW.kg	resp.type	dose.units	appl.dose	N	Y	N.m.Y	BMR.type	BMR	ABioactDCVCBW34.median	AMetGSHBW34.median	AMetLiv1BW34.median	AMetLngBW34.median	AUCCBld.median	TotMetabBW34.median	TotOxMetabBW34.median
78	103	0.714286	0.71429	1	1	0.2053	dichot	mg.kgd	0	49	1	48	extra	0.1	0	0	0	0	0	0	0
79	103	0.714286	0.71429	1	1	0.2053	dichot	mg.kgd	500	43	0	43	extra	0.1	3.35598	3.305095	629.1555	18.6803	1249.58	673.415	666.8265
80	103	0.714286	0.71429	1	1	0.2053	dichot	mg.kgd	1000	38	5	33	extra	0.1	7.54951	7.45467	842.3075	27.52865	3077.31	906.8165	895.2005
81	103	0.714286	0.71429	1	1	0.2053	dichot	mg.kgd	0	49	1	48	extra	0.05	0	0	0	0	0	0	0
82	103	0.714286	0.71429	1	1	0.2053	dichot	mg.kgd	500	43	0	43	extra	0.05	3.35598	3.305095	629.1555	18.6803	1249.58	673.415	666.8265
83	103	0.714286	0.71429	1	1	0.2053	dichot	mg.kgd	1000	38	5	33	extra	0.05	7.54951	7.45467	842.3075	27.52865	3077.31	906.8165	895.2005
84	103	0.714286	0.71429	1	1	0.372	dichot	mg.kgd	0	47	0	47	extra	0.1	0	0	0	0	0	0	0
85	103	0.714286	0.71429	1	1	0.352	dichot	mg.kgd	500	36	1	35	extra	0.1	4.157795	4.13705	750.1395	22.98315	1392.33	798.2335	789.6185
86	103	0.714286	0.71429	1	1	0.34	dichot	mg.kgd	1000	34	3	31	extra	0.1	9.40237	9.34745	990.3775	33.6115	3440.69	1075.235	1054.515
87	103	0.714286	0.71429	1	1	0.372	dichot	mg.kgd	0	47	0	47	extra	0.05	0	0	0	0	0	0	0
88	103	0.714286	0.71429	1	1	0.352	dichot	mg.kgd	500	36	1	35	extra	0.05	4.157795	4.13705	750.1395	22.98315	1392.33	798.2335	789.6185
89	103	0.714286	0.71429	1	1	0.34	dichot	mg.kgd	1000	34	3	31	extra	0.05	9.40237	9.34745	990.3775	33.6115	3440.69	1075.235	1054.515
90	103	0.714286	0.71429	1	1	0.2967	dichot	mg.kgd	0	46	17	32	extra	0.1	0	0	0	0	0	0	0
91	103	0.714286	0.71429	1	1	0.2967	dichot	mg.kgd	500	31	21	10	extra	0.1	3.889655	3.848505	710.059	21.6093	1343.585	756.28	748.3835
92	103	0.714286	0.71429	1	1	0.2967	dichot	mg.kgd	1000	38	32	6	extra	0.1	8.85263	8.78898	946.9695	31.91265	3335.605	1028.26	1010.335
93	103	0.714286	0.71429	1	1	0.2967	dichot	mg.kgd	0	36	17	32	extra	0.1	0	0	0	0	0	0	0
94	103	0.714286	0.71429	1	1	0.2967	dichot	mg.kgd	500	23	21	10	extra	0.1	3.889655	3.848505	710.059	21.6093	1343.585	756.28	748.3835
95	103	0.714286	0.71429	1	1	0.2967	dichot	mg.kgd	1000	33	32	6	extra	0.1	8.85263	8.78898	946.9695	31.91265	3335.605	1028.26	1010.335
96	103	0.714286	0.71429	1	1	0.478	dichot	mg.kgd	0	49	0	49	extra	0.1	0	0	0	0	0	0	0
97	103	0.714286	0.71429	1	1	0.461	dichot	mg.kgd	500	44	6	38	extra	0.1	4.638285	4.65031	818.0065	25.3394	1468.565	873.3005	863.4225
98	103	0.714286	0.71429	1	1	0.428	dichot	mg.kgd	1000	35	2	33	extra	0.1	10.39305	10.31195	1073.945	36.6973	3615.66	1159.9	1133.22
99	103	0.714286	0.71429	1	1	0.478	dichot	mg.kgd	0	37	0	49	extra	0.1	0	0	0	0	0	0	0

	A	B	C	D	E	F	G	H	I	J	K	L	M	N
1	GRP	study	notes	organ	type.endpt	endpoint	species	strain	sex	route	exp.regime	hrs.day	days.wk	expos. wk
100	28.2	NTP88.p3	500 mg/kg-d dose group	Kidney	cancer	car+ad	rat	Osborne-Mendel	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103
101	28.2	NTP88.p3	1000 mg/kg-d dose group	Kidney	cancer	car+ad	rat	Osborne-Mendel	M	oral	5d/w, 104 wk dosed, 105 wk ctrl	24	5	103

	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA	AB	AC	AD	AE	AF	AG	AH	AI
1	sac.wk	adjust	adj.hd	adj.exp	adj.sac	BW.kg	resp.type	dose.units	appl.dose	N	Y	N.m.Y	BMR.type	BMR	ABioactDCVCBW34.median	AMetGSHBW34.median	AMetLiv1BW34.median	AMetLngBW34.median	AUCCBld.median	TotMetabBW34.median	TotOxMetabBW34.median
100	103	0.714286	0.71429	1	1	0.461	dichot	mg.kgd	500	34	6	38	extra	0.1	4.638285	4.65031	818.0065	25.3394	1468.565	873.3005	863.4225
101	103	0.714286	0.71429	1	1	0.428	dichot	mg.kgd	1000	27	2	33	extra	0.1	10.39305	10.31195	1073.945	36.6973	3615.66	1159.9	1133.22